Avalo Therapeutics, Inc.
News
(2)April 2026
Avalo Therapeutics, Inc. — ARS Filing
# 🧾 What This Document Is This is Avalo Therapeutics' **Annual Report to Shareholders (ARS)** for 2025. Think of it as the company's official, detailed year-in-review summary sent to its owners (the shareholders). It combines the comprehensive business and financial reporting of a formal 10-K fili
Avalo Therapeutics, Inc. — DEF 14A Filing
# 📄 What This Document Is This is a **Definitive Proxy Statement (DEF 14A)** for Avalo Therapeutics. Think of it as an invitation and information packet for the company's big annual shareholder meeting. It explains what will be voted on, who is running the company, and how much the leaders get paid
Peers in Biotechnology
Vertex Pharmaceuticals Incorporated
Regeneron Pharmaceuticals, Inc.
argenx SE
Alnylam Pharmaceuticals, Inc.
BeOne Medicines AG
Insmed Incorporated
Royalty Pharma plc
BioNTech SE
Roivant Sciences Ltd.
Moderna, Inc.